MHRA approves Lynavoy for PBC itching treatment
In its announcement on 1 May 2026, the MHRA said it had approved linerixibat, sold as Lynavoy, for adults with primary biliary cholangitis, or PBC, who have itching linked to the condition. That makes it a new licensed option in the UK for a symptom that can sound minor when you first hear it, but can wear people down over time. If you are new to this story, it helps to begin with the basic point: this is not a broad approval for every liver problem. It is a specific decision about treating itch in adults with PBC, and that precision is a big part of how medicine approvals work.
PBC is a disease in which the bile ducts in the liver become damaged. According to the MHRA, that damage can lead to a build-up of bile acids in the blood, and that build-up is thought to be one reason some patients experience itching. That matters because itching is not only about discomfort. It can disturb sleep, affect concentration and make ordinary routines harder. So when regulators and researchers talk about relief from itching, they are also talking about quality of life, rest and the ability to get through the day.
The MHRA says linerixibat works by reducing the build-up of substances in the body, including bile acids, and that this can help reduce itching. The medicine is taken as an oral film-coated tablet, with a recommended dose of one tablet twice a day. For readers trying to make sense of the wording, the useful takeaway is simple. Lynavoy is meant to ease a symptom linked to PBC, and it is designed to be taken in tablet form rather than given by injection or infusion. That can make a difference to how easily a treatment fits into daily life.
The evidence behind the decision came from a global Phase 3 clinical trial called Glisten. In that study, 238 patients were randomly assigned to receive either linerixibat 40 mg twice daily or a placebo for 24 weeks. Phase 3 is usually one of the final major stages before a medicine is considered for approval. A placebo is a lookalike treatment without the active medicine, and random assignment helps researchers compare groups fairly. In other words, this is the point where regulators look for solid evidence that a treatment does more than people would expect by chance alone.
According to the MHRA, the Glisten trial showed that linerixibat significantly reduced itching and improved sleep disruption caused by itching. The study’s main measure, the Monthly Itch Score, showed a statistically significant improvement in the group taking linerixibat compared with the group given placebo. That phrase, statistically significant, can sound cold or overly technical. Here, it means the difference between the two groups was strong enough that researchers did not treat it as random variation. It does not mean every patient will respond in exactly the same way, but it does mean the study found a real average benefit in the treated group.
The approval was granted on 1 May 2026 to GlaxoSmithKline UK Limited through the National Procedure. The MHRA also said it will continue to monitor the safety and effectiveness of linerixibat as it is used more widely. This is an important part of the story. Approval is not the end of checking. A regulator reviews the evidence before granting a licence, but it also keeps watching afterwards, because wider real-world use can show patterns that may not fully appear in a trial involving 238 patients.
For patients, families and anyone trying to read this news carefully, the final lesson is about reporting. The MHRA says the full list of reported side effects can be found in Section 4 of the Patient Information Leaflet or in the Summary of Product Characteristics, which will be published on the MHRA products website within seven days of approval. Anyone who thinks they may be having a side effect is encouraged to speak to a doctor, pharmacist or nurse and report it through the Yellow Card scheme. Why does that matter? Because medicine safety does not depend only on one trial or one approval date. It also depends on people reporting what happens after a drug reaches everyday care. So the Lynavoy decision is both a treatment story and a useful reminder of how drug regulation works in practice: evidence first, licensing next, and careful monitoring after that.